Compare Stocks: PHGE, JSPR, GNTA, and MRKR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNTA Genenta Science	$0.70	$1.21	$0.55 ▼ $10.00	$16.54M	0.73	53,453 shs	78,464 shs
JSPR Jasper Therapeutics	$0.62	$0.71	$0.32 ▼ $2.69	$20.56M	3.04	320,387 shs	222,807 shs
MRKR Marker Therapeutics	$1.18	$1.24	$0.84 ▼ $2.46	$19.67M	1.53	70,729 shs	47,274 shs
PHGE BiomX	$1.85	$1.70	$1.19 ▼ $122.93	$4.94M	1.33	364,372 shs	3.33 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNTA Genenta Science	0.00%	-16.60%	-44.35%	-63.48%	-75.95%
JSPR Jasper Therapeutics	0.00%	-6.44%	-13.72%	+23.19%	-75.29%
MRKR Marker Therapeutics	0.00%	+2.61%	-15.11%	-13.87%	+24.21%
PHGE BiomX	0.00%	0.00%	+34.55%	-58.89%	-98.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNTA Genenta Science	$0.70	$1.21	$0.55 ▼ $10.00	$16.54M	0.73	53,453 shs	78,464 shs
JSPR Jasper Therapeutics	$0.62	$0.71	$0.32 ▼ $2.69	$20.56M	3.04	320,387 shs	222,807 shs
MRKR Marker Therapeutics	$1.18	$1.24	$0.84 ▼ $2.46	$19.67M	1.53	70,729 shs	47,274 shs
PHGE BiomX	$1.85	$1.70	$1.19 ▼ $122.93	$4.94M	1.33	364,372 shs	3.33 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNTA Genenta Science	0.00%	-16.60%	-44.35%	-63.48%	-75.95%
JSPR Jasper Therapeutics	0.00%	-6.44%	-13.72%	+23.19%	-75.29%
MRKR Marker Therapeutics	0.00%	+2.61%	-15.11%	-13.87%	+24.21%
PHGE BiomX	0.00%	0.00%	+34.55%	-58.89%	-98.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNTA Genenta Science	1.00	Sell	N/A	N/A
JSPR Jasper Therapeutics	2.50	Moderate Buy	$8.17	1,221.89% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	747.46% Upside
PHGE BiomX	2.00	Hold	$260.00	13,954.05% Upside

Current Analyst Ratings Breakdown

Latest PHGE, JSPR, GNTA, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/6/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.29 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
MRKR Marker Therapeutics	$3.55M	5.54	N/A	N/A	$1.01 per share	1.17
PHGE BiomX	N/A	N/A	N/A	N/A	($124.99) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNTA Genenta Science	-$7.39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-884.17%	-143.83%	11/9/2026 (Estimated)
MRKR Marker Therapeutics	-$12.16M	-$0.41	N/A	N/A	N/A	-343.03%	-56.96%	-47.82%	11/12/2026 (Estimated)
PHGE BiomX	-$36.20M	-$3.21	N/A	N/A	N/A	N/A	N/A	-165.38%	11/11/2026 (Estimated)

Latest PHGE, JSPR, GNTA, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	PHGE BiomX	N/A	-$3.70	N/A	-$3.70	N/A	$0.33 million
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNTA Genenta Science	0.35	14.16	14.16
JSPR Jasper Therapeutics	N/A	1.48	1.47
MRKR Marker Therapeutics	N/A	6.03	6.03
PHGE BiomX	0.02	0.24	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNTA Genenta Science	15.13%
JSPR Jasper Therapeutics	79.85%
MRKR Marker Therapeutics	22.39%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
GNTA Genenta Science	28.99%
JSPR Jasper Therapeutics	3.90%
MRKR Marker Therapeutics	5.70%
PHGE BiomX	0.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNTA Genenta Science	9	23.59 million	16.75 million	Not Optionable
JSPR Jasper Therapeutics	22	33.28 million	31.98 million	Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable
PHGE BiomX	120	2.67 million	2.67 million	N/A

PHGE, JSPR, GNTA, and MRKR Headlines

Recent News About These Companies

BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 83.3% in August

September 18 at 4:21 AM | americanbankingnews.com

Tessera Defense and Homeland Security CEO Issues Letter to Shareholders

September 15, 2026 | globenewswire.com

Tessera Begins Trading Under HLSQ as Demand Grows for Connected Physical Security

September 11, 2026 | finance.yahoo.com

BiomX Announces Reverse Stock Split and Rebranding Plan

September 9, 2026 | tipranks.com

BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows

September 4, 2026 | globenewswire.com

BiomX To Rebrand As Tessera Defense; Adopts HLSQ Ticker;Stock Up

September 1, 2026 | rttnews.com

BiomX Inc. to Rename Itself Tessera Defense and Homeland Security Inc. and Change NYSE American Ticker to HLSQ

September 1, 2026 | quiverquant.comQ

BiomX Inc. to Become Tessera Defense and Homeland Security Inc.

September 1, 2026 | globenewswire.com

BiomX Shareholders Approve One-for-Ten Reverse Split

August 28, 2026 | tipranks.com

BiomX Shareholders Approve Mandragola Deal and Reverse Split

August 25, 2026 | tipranks.com

BiomX delays quarterly filing amid acquisitions and audit

August 14, 2026 | tipranks.com

BiomX subsidiary Zorronet wins $300,000 order

August 14, 2026 | msn.com

BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site

August 14, 2026 | globenewswire.com

BiomX Invests in MEA Motor and Drone Testing

August 11, 2026 | tipranks.com

BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems

August 5, 2026 | globenewswire.com

BiomX Amends Zorronet Acquisition Terms

July 28, 2026 | finance.yahoo.com

BiomX Amends Promissory Note, Issues Restricted Shares

July 28, 2026 | tipranks.com

BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms

July 28, 2026 | globenewswire.com

BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe

July 24, 2026 | globenewswire.com

BiomX Cancels Conversion Shares to Restore NYSE Compliance

July 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, JSPR, GNTA, and MRKR Company Descriptions

Genenta Science NASDAQ:GNTA

$0.70 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.69 -0.01 (-1.17%)

As of 07:34 AM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Jasper Therapeutics NASDAQ:JSPR

$0.62 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.59 -0.03 (-5.15%)

As of 09/18/2026 05:16 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Marker Therapeutics NASDAQ:MRKR

$1.18 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.19 +0.01 (+0.85%)

As of 04:00 AM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

BiomX NYSEAMERICAN:PHGE

$1.85 0.00 (0.00%)

As of 09/10/2026

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHGE, JSPR, GNTA, and MRKR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHGE, JSPR, GNTA, and MRKR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHGE, JSPR, GNTA, and MRKR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, JSPR, GNTA, and MRKR Company Descriptions

Genenta Science NASDAQ:GNTA

Jasper Therapeutics NASDAQ:JSPR

Marker Therapeutics NASDAQ:MRKR

BiomX NYSEAMERICAN:PHGE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHGE, JSPR, GNTA, and MRKR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHGE, JSPR, GNTA, and MRKR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHGE, JSPR, GNTA, and MRKR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, JSPR, GNTA, and MRKR Company Descriptions

Genenta Science NASDAQ:GNTA

Jasper Therapeutics NASDAQ:JSPR

Marker Therapeutics NASDAQ:MRKR

BiomX NYSEAMERICAN:PHGE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools